GlassScriptPhysician profile
Rachel Redlin
NPI 1922750546
$2,115.34
in general payments reported to CMS, 2019-2025
25 companies · $870 in 2025
The $870 reported for 2025 was more than what 83% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $376 · 2024: $870 · 2025: $870.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,666 · Education: $449.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,666.35 |
| Education | $448.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $242.00 | 2024 | Enhertu |
| Glaxosmithkline, LLC. | $223.16 | 2024-2025 | Ojjaara, Jemperli, Zejula |
| Seagen INC. | $198.00 | 2023 | |
| Gilead Sciences, INC. | $193.05 | 2025 | Trodelvy |
| Merck Sharp & Dohme LLC | $163.81 | 2024-2025 | Keytruda, Lynparza |
| Genentech USA, INC. | $136.49 | 2024-2025 | Tecentriq |
| Eisai INC. | $124.03 | 2023-2025 | |
| Novartis Pharmaceuticals Corporation | $117.11 | 2023-2025 | Kisqali, Piqray |
| Puma Biotechnology, INC. | $104.69 | 2023-2025 | Nerlynx |
| Astrazeneca Pharmaceuticals LP | $91.73 | 2024-2025 | Enhertu |
| Takeda Pharmaceuticals U.S.A., INC. | $84.62 | 2025 | Alunbrig |
| Janssen Biotech, INC. | $60.08 | 2024-2025 | Tecvayli, Darzalex, Akeega |
| Abbvie INC. | $50.62 | 2024-2025 | |
| Exelixis INC. | $50.14 | 2025 | Cabometyx |
| Array Biopharma INC | $46.24 | 2024 | Mektovi, Braftovi, Tukysa |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aveo Pharmaceuticals, INC. | $45.64 | 2023-2024 | Fotivda |
| Biocon Biologics INC | $26.12 | 2024 | Ogivri |
| Genzyme Corporation | $25.75 | 2025 | |
| Geron Corporation | $23.47 | 2025 | Rytelo |
| Pharmaessentia USA Corporation | $21.03 | 2025 | Besremi |
| Astellas Pharma US INC | $18.59 | 2025 | Vyloy |
| Incyte Corporation | $18.30 | 2023 | Jakafi |
| Servier Pharmaceuticals LLC | $18.05 | 2025 | |
| Novocure INC. | $16.52 | 2025 | Optune Lua (Novottf-200t) |
| Pfizer INC. | $16.10 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rachel Redlin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.